We used a multiplexed bead-based assay to screen for autoantibodies targeting representative type I IFNs (IFNα2, IFNβ, and IFNω; [2]) in a cohort of 103 individuals (179 samples from 80 males, aged 31 to 81; and 51 samples from 23 females, aged 20 to 87; overall median age 66) who were admitted to the ICU of the University Hospital Zurich with severe COVID-19 between March 2020 and April 2021 (Table 1). Here, IFNA2 is linked to COVID-19.